|
Sign In to gain access to subscriptions and/or personal tools.
|
Toxicologic Pathology, Vol. 28, No. 1,
171-177 (2000)
DOI: 10.1177/019262330002800122
© 2000 Society of Toxicologic Pathology
A Mouse Model for Glioma: Biology, Pathology, and Therapeutic Opportunities
Eric C. Holland
M.D. Anderson Cancer Center, Department of Neurosurgery, Houston, Texas 77030
The epidermal growth factor receptor (EGFR) gene is amplified or mutated in 30-50% of human glioblastoma multiforme. These mutations are usually associated with deletions of the INK4 -ARF locus, which encodes 2 gene products (p16INK4a and p19ARF) involved in cell cycle arrest and apoptosis. We have investigated the role of EGFR mutation in gliomagenesis using avian retroviral vectors to transfer a mutant EGFR gene to glial precursors and astrocytes in transgenic mice. These mice express tv-a, a gene encoding the retrovirus receptor TVA, which is under the control of brain cell type-specific promoters. We demonstrate that expression of a constitutively active, mutant form of EGFR in cells in the glial lineage can induce lesions with many similarities to human gliomas, including increased cell density, vascular proliferation, and immunohistochemical staining for glial fibrillary acidic protein (GFAP) and nestin. We also demonstrate that primary astrocytes cultured from transgenic mice expressing tv-a from the GFAP promoter are efficiently infected in culture, and such genetically modified cell cultures can be tumorigenic in nude mice. The combinations of genetic lesions (eg, mutated EGFR, INK4a-/-) leading to tumor formation in these 2 mouse systems are similar to those found in human gliomas. These genetically defined animal models for gliomas will allow for the testing of therapies that are targeted specifically at the gene products involved in the pathogenesis of gliomas.
Key Words: Epidermal growth factor receptor (EGRF) gene INK4a-ARF gliomagenesis signal transduction cell cycle arrest

CiteULike Connotea Del.icio.us Digg Reddit Technorati What's this?
This article has been cited by other articles:

|
 |

|
 |
 
J. N. Sarkaria, G. J. Kitange, C. D. James, R. Plummer, H. Calvert, M. Weller, and W. Wick
Mechanisms of Chemoresistance to Alkylating Agents in Malignant Glioma
Clin. Cancer Res.,
May 15, 2008;
14(10):
2900 - 2908.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
J. P. Morton, M. E. Mongeau, D. S. Klimstra, J. P. Morris, Y. C. Lee, Y. Kawaguchi, C. V. E. Wright, M. Hebrok, and B. C. Lewis
Sonic hedgehog acts at multiple stages during pancreatic tumorigenesis
PNAS,
March 20, 2007;
104(12):
5103 - 5108.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
C. Allen, S. Vongpunsawad, T. Nakamura, C. D. James, M. Schroeder, R. Cattaneo, C. Giannini, J. Krempski, K.-W. Peng, J. M. Goble, et al.
Retargeted Oncolytic Measles Strains Entering via the EGFRvIII Receptor Maintain Significant Antitumor Activity against Gliomas with Increased Tumor Specificity
Cancer Res.,
December 15, 2006;
66(24):
11840 - 11850.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S. Gil-Perotin, M. Marin-Husstege, J. Li, M. Soriano-Navarro, F. Zindy, M. F. Roussel, J.-M. Garcia-Verdugo, and P. Casaccia-Bonnefil
Loss of p53 Induces Changes in the Behavior of Subventricular Zone Cells: Implication for the Genesis of Glial Tumors
J. Neurosci.,
January 25, 2006;
26(4):
1107 - 1116.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
C. M. Carlson, J. L. Frandsen, N. Kirchhof, R. S. McIvor, and D. A. Largaespada
Somatic integration of an oncogene-harboring Sleeping Beauty transposon models liver tumor development in the mouse
PNAS,
November 22, 2005;
102(47):
17059 - 17064.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
H. D. Hemmati, I. Nakano, J. A. Lazareff, M. Masterman-Smith, D. H. Geschwind, M. Bronner-Fraser, and H. I. Kornblum
Cancerous stem cells can arise from pediatric brain tumors
PNAS,
December 9, 2003;
100(25):
15178 - 15183.
[Abstract]
[Full Text]
[PDF]
|
 |
|
|